Treatment of multiple sclerosis - success from bench to bedside.,Nature Reviews Neurology

当前位置： X-MOL 学术 › Nat. Rev. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment of multiple sclerosis - success from bench to bedside.
Nature Reviews Neurology ( IF 28.2 ) Pub Date : 2019-01-01 , DOI: 10.1038/s41582-018-0082-z
Mar Tintore ₁ , Angela Vidal-Jordana ₁ , Jaume Sastre-Garriga ₁

Affiliation

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval of IFNβ and glatiramer acetate for the treatment of relapsing-remitting MS. Ten years later, the first monoclonal antibody, natalizumab, was approved, followed by a third important landmark with the introduction of oral medications, initially fingolimod and then teriflunomide, dimethyl fumarate and cladribine. Concomitantly, new monoclonal antibodies (alemtuzumab and ocrelizumab) have been developed and approved. The modern era of MS therapy reached primary progressive MS in 2018, with the approval of ocrelizumab. We have also learned the importance of starting treatment early and the importance of clinical and MRI monitoring to assess treatment response and safety. Treatment decisions should account for disease phenotype, prognostic factors, comorbidities, the desire for pregnancy and the patient's preferences in terms of acceptable risk. The development of treatment for MS during the past 25 years is a fantastic success of translational medicine.

中文翻译：

多发性硬化症的治疗 - 从工作台到床边的成功。

多发性硬化症 (MS) 治疗的现代时代始于 25 年前，当时 IFNβ 和醋酸格拉替雷获批用于治疗复发缓解型 MS。十年后，第一个单克隆抗体那他珠单抗获得批准，随后是第三个重要里程碑，引入了口服药物，首先是芬戈莫德，然后是特立氟胺、富马酸二甲酯和克拉屈滨。与此同时，新的单克隆抗体（alemtuzumab 和 ocrelizumab）也被开发和批准。随着 ocrelizumab 的批准，MS 治疗的现代时代在 2018 年达到了原发性进行性 MS。我们还了解到早期开始治疗的重要性以及临床和 MRI 监测对评估治疗反应和安全性的重要性。治疗决策应考虑疾病表型、预后因素、合并症、怀孕的愿望和患者在可接受风险方面的偏好。过去 25 年中 MS 治疗的发展是转化医学的巨大成功。

更新日期：2019-01-26

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南